Sight Sciences Q2 revenue $23.5M (+36% YoY); net loss narrows to $14.8M; reaffirms FY guidance

Sight Sciences, Inc.

2023-Q2 EPS reported -$0.66 revenue$42,296,000

Revenue $23.5M, +36% YoY; Surgical Glaucoma $21.4M (+35%), Dry Eye $2.1M (+56%).
Net loss $14.8M ($0.30/share) vs $23.8M ($0.50) prior year; operating expenses down 6%.
Gross margin 85.6% (vs 84.1% prior year); cash $154.5M; long-term debt $35.0M.
FY2023 revenue guidance reaffirmed at $89-94M (25-32% YoY growth); quarterly adjusted opex ~$30.5M.
SAHARA trial met primary signs endpoint at 6 months; Cigna covers OMNI procedures (15M lives).

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Sight Sciences, Inc. reported the second quarter ended June 30, 2023 results: revenue $23.5 million. Guidance reaffirmed.

Period: the second quarter ended June 30, 2023
Revenue: $23.5 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

second quarter ended June 30, 2023 and reaffirmed guidance for full year 2023. Recent Business and Financial Highlights • Generated record second quarter 2023 total revenue of $23.5 million, an increase of 36% compared to the prior year period • Achieved total gross margin of 85.6% in the second quarter of 2023 compared to 84.1% in the prior year period Dry Eye

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Sight Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-037968

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.